Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NAPOLI-2
NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer
- NCT04005339 ↗
- Active, not recruiting
- Georgetown University
- Focused
We haven't built an HCP commentary report on NAPOLI-2 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NAPOLI-2 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- NAPOLI-2: Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract Cancer
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Advanced Biliary Tract Cancer
- Interventions
- Nanoliposomal Irinotecan; Leucovorin; Fluorouracil
- Arms
- Single Arm · Experimental
- Enrollment
- 48
- Primary outcomes
- The Efficacy of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Advanced Biliary Tract Cancers Following Progression on or Intolerance of Gemcitabine and Platinum Chemotherapy.
- Sponsor
- Georgetown University with Ipsen
- Start
- Jul 29, 2019
- Primary completion
- Sep 3, 2025
- Results posted
- Yes
- Registry record
- NCT04005339 · updated Oct 27, 2026